| Product Code: ETC200136 | Publication Date: Jul 2023 | Updated Date: Jul 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 60 | No. of Figures: 40 | No. of Tables: 7 |
The India Nuclear Medicine Radioisotopes Market was estimated at USD 1181 Million in 2025 and is projected to reach USD 1687 Million by 2032, growing at a CAGR of 5.2% from 2026 to 2032. This impressive growth trajectory is primarily driven by the increasing prevalence of cancer and the rising geriatric population in India. Furthermore, the expansion of PET imaging centers across the country and advancements in radiopharmaceuticals are facilitating a more significant utilization of radioisotopes, enhancing their role in diagnostics and treatment.
This graph highlights how the India Nuclear Medicine Radioisotopes Market has steadily grown over the years, supported by major growth factors.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate | Major Drivers |
| 2021 | -3.1% | Decreased investment in healthcare facilities |
| 2022 | 8.8% | Growing demand for advanced diagnostics |
| 2023 | 7.8% | Expansion of healthcare infrastructure projects |
| 2024 | 7.1% | Increased funding for research initiatives |
| 2025 | 7.3% | Rise in aging population statistics |
| 2026 | 7.8% | Surge in preventive health screenings |
| 2027 | 6.0% | Development of innovative imaging technologies |
| 2028 | 6.6% | Growing partnerships with global firms |
| 2029 | 6.4% | Enhanced awareness of health benefits |
| 2030 | 6.2% | Increase in government healthcare spending |
| 2031 | 6.4% | enhanced product quality standards |
| 2032 | 6.3% | Rising prevalence of chronic diseases |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
The landscape of the India Nuclear Medicine Radioisotopes Market is evolving rapidly, primarily driven by an upsurge in demand for precision medicine. With cancer rates climbing and the population aging, healthcare providers are increasingly turning to nuclear medicine for accurate diagnostics. The expansion of PET imaging centers in urban areas is making these advanced diagnostic tools more accessible, thus enhancing early disease detection.
Moreover, the emergence of advanced radiopharmaceuticals is reshaping the market dynamics, allowing for targeted therapies and better patient outcomes. The Indian government's favorable initiatives, including the Make In India scheme, are also encouraging local production of radioisotopes, thereby contributing to market growth.
Despite the promising growth prospects, the India Nuclear Medicine Radioisotopes Market faces significant challenges, primarily linked to the high production and maintenance costs associated with radioactive isotopes. The intricate manufacturing processes, which require expensive equipment like cyclotrons and specialized chemicals for purification, result in elevated costs. This can limit access to critical radioisotopes for smaller healthcare providers and institutions, impacting overall market adoption and growth potential.
Several trends are shaping the future of the India Nuclear Medicine Radioisotopes Market. The move towards personalized medicine is gaining traction, with advancements in targeted therapies becoming more prevalent. Additionally, innovations in imaging technologies are enhancing the ability of healthcare professionals to conduct more precise diagnoses. The integration of artificial intelligence in imaging analysis is also on the rise, promising to improve efficiency and diagnostic accuracy.
Opportunities abound in the India Nuclear Medicine Radioisotopes Market, particularly in rural areas where access to diagnostic facilities remains limited. Expanding PET imaging centers in underserved regions presents a pathway to reach a broader patient population. Additionally, partnerships between public and private sectors could pave the way for more affordable production solutions, enhancing accessibility to crucial diagnostic tools. Investment in research and development of novel radiopharmaceuticals also offers substantial potential for future growth.
The Indian government has launched several initiatives aimed at boosting the nuclear medicine sector. Programs under the Make In India campaign are designed to promote domestic manufacturing of medical equipment and radioisotopes, thereby reducing reliance on imports. Investment in public health initiatives, alongside research grants, encourages innovation and development in the radiopharmaceutical space, ultimately benefiting healthcare delivery across the nation.
Looking ahead to 2026-2032, the India Nuclear Medicine Radioisotopes Market is poised for robust growth. Continued advancements in diagnostic imaging and the increasing emphasis on early detection and personalized treatment are likely to dominate the landscape. Furthermore, as healthcare infrastructure continues to evolve, the availability of advanced therapeutic options will further enhance the role of nuclear medicine in healthcare delivery, ultimately improving patient outcomes and expanding the market.
Recent developments in the India Nuclear Medicine Radioisotopes Market have been marked by increased partnerships between research institutions and healthcare providers. Innovations in radioisotope production techniques are also underway, which are expected to improve efficiency and reduce costs. As hospitals and clinics rebound from the COVID-19 pandemic, there is a notable resurgence in the demand for nuclear medicine, underscoring the market's critical role in comprehensive patient care.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Nuclear Medicine Radioisotopes Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Nuclear Medicine Radioisotopes Market Revenues & Volume, 2022 & 2032F |
3.3 India Nuclear Medicine Radioisotopes Market - Industry Life Cycle |
3.4 India Nuclear Medicine Radioisotopes Market - Porter's Five Forces |
3.5 India Nuclear Medicine Radioisotopes Market Revenues & Volume Share, By Types, 2022 & 2032F |
3.6 India Nuclear Medicine Radioisotopes Market Revenues & Volume Share, By Application, 2022 & 2032F |
4 India Nuclear Medicine Radioisotopes Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of cancer and other chronic diseases requiring nuclear medicine diagnostics and treatments |
4.2.2 Growing awareness and acceptance of nuclear medicine procedures in India |
4.2.3 Technological advancements in nuclear medicine imaging and therapy |
4.3 Market Restraints |
4.3.1 High initial setup and operational costs associated with nuclear medicine facilities |
4.3.2 Regulatory challenges and stringent government approvals for handling radioisotopes |
4.3.3 Limited availability of skilled professionals in the field of nuclear medicine |
5 India Nuclear Medicine Radioisotopes Market Trends |
6 India Nuclear Medicine Radioisotopes Market, By Types |
6.1 India Nuclear Medicine Radioisotopes Market, By Types |
6.1.1 Overview and Analysis |
6.1.2 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Types, 2022-2032F |
6.1.3 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Technetium-99m (Tc-99m), 2022-2032F |
6.1.4 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Thallium-201 (Tl-201), 2022-2032F |
6.1.5 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Iodine (I-123), 2022-2032F |
6.1.6 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Fluorine-18, 2022-2032F |
6.1.7 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Rubidium-82 (Rb-82), 2022-2032F |
6.1.8 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Iodine-131 (I-131), 2022-2032F |
6.1.9 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Others, 2022-2032F |
6.1.10 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Others, 2022-2032F |
6.2 India Nuclear Medicine Radioisotopes Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Oncology, 2022-2032F |
6.2.3 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Cardiology, 2022-2032F |
6.2.4 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Thyroid, 2022-2032F |
6.2.5 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Neurology, 2022-2032F |
6.2.6 India Nuclear Medicine Radioisotopes Market Revenues & Volume, By Others, 2022-2032F |
7 India Nuclear Medicine Radioisotopes Market Import-Export Trade Statistics |
7.1 India Nuclear Medicine Radioisotopes Market Export to Major Countries |
7.2 India Nuclear Medicine Radioisotopes Market Imports from Major Countries |
8 India Nuclear Medicine Radioisotopes Market Key Performance Indicators |
8.1 Number of nuclear medicine procedures performed annually in India |
8.2 Investment in research and development of new radioisotopes and nuclear medicine technologies |
8.3 Adoption rate of nuclear medicine procedures in different regions of India |
9 India Nuclear Medicine Radioisotopes Market - Opportunity Assessment |
9.1 India Nuclear Medicine Radioisotopes Market Opportunity Assessment, By Types, 2022 & 2032F |
9.2 India Nuclear Medicine Radioisotopes Market Opportunity Assessment, By Application, 2022 & 2032F |
10 India Nuclear Medicine Radioisotopes Market - Competitive Landscape |
10.1 India Nuclear Medicine Radioisotopes Market Revenue Share, By Companies, 2025 |
10.2 India Nuclear Medicine Radioisotopes Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here